Diabetes mellitus is one among the leading causes of morbidity worldwide and is anticipated to rise substantially over subsequent decades. Several investigations have demonstrated a better susceptibility to some infectious diseases in diabetic people, like Staphylococcus aureus and Mycobacterium tuberculosis, 7-9 probably due to the dysregulated system. Therefore, these diabetic patients might be at increased risk of COVID‐19 and have a poorer prognosis. Since virus infection may cause sharp fluctuation of blood sugar level of diabetes patients, which adversely affect the recovery of patients, there's a reason to suspect that diabetes combined with SARS‐CoV‐2 pneumonia may form a vicious circle, which is detrimental to the prognosis of COVID‐19. Whether interference from other comorbidities is present or not; SARS‐CoV‐2 pneumonia patients with diabetes are more severe than those without diabetes evaluating from organ damage, inflammatory factors or hypercoagulability, and are more likely to progress into a worse prognosis. Therefore, diabetes might be considered as a risk factor for the result of SARS‐CoV‐2 pneumonia, and more intensive attention should be paid to patients with diabetes, just in case of rapid deterioration.

A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.scholarscentral.org/submissions/asian-biomedical-pharmaceutical-sciences.html) or forwarded to the Editorial Office at  jbiopharm@scholarlypub.com.

Media Contact:                       

Alina Grace            

Journal Manager

Asian Journal of Biomedical & Pharmaceutical Sciences

Email: jbiopharm@scholarlypub.com